Ana Balkandjieva

1 week ago | hepcoalition.org | Ana Balkandjieva |Sophia Abene |Sarah Rowan

A newly published scoping review in Open Forum Infectious Diseases shows that integrating Hepatitis C virus (HCV) treatment into syringe services programs significantly improves treatment initiation and cure rates among people who inject drugs. This population has historically faced major barriers to accessing care. The review analyzed 13 studies from across the United States.

1 month ago | hepcoalition.org | Ana Balkandjieva |Priya Venkatesan

WHO has prequalified the first self-test for hepatitis C virus (HCV), specifically designed for lay users. The burden of HCV infections still poses a substantial global health challenge. Despite the development of direct-acting antiviral therapies with response rates of more than 95%, limited access to diagnostic tests and treatment has resulted in chronic infection and consequential serious illness and progressive liver damage for millions of individuals worldwide.

Dec 11, 2024 | hepcoalition.org | Ana Balkandjieva

Despite available curative treatments, global rates of hepatitis C virus (HCV) infection persist with significant burden in low- and middle-income countries (LMICs). Long-acting (LA) antiviral products are in development. A study, published in the , explored the challenges and opportunities in LA-HCV treatment across three LMICs: Egypt, Ethiopia and India. The survey focused on understanding barriers and facilitators to treatment, with emphasis on LA treatment preferences.

Dec 11, 2024 | hepcoalition.org | Ana Balkandjieva

Despite available curative treatments, global rates of hepatitis C virus (HCV) infection persist with significant burden in low- and middle-income countries (LMICs). Long-acting (LA) antiviral products are in development. A study, published in the , explored the challenges and opportunities in LA-HCV treatment across three LMICs: Egypt, Ethiopia and India. The survey focused on understanding barriers and facilitators to treatment, with emphasis on LA treatment preferences.

Dec 10, 2024 | hepcoalition.org | Ana Balkandjieva

Harm reduction The Global State of Harm Reduction is the only report that provides an independent analysis of harm reduction in the world. Now in its ninth edition, the Global State of Harm Reduction 2024 is the most comprehensive global mapping of harm reduction responses to drug use, HIV and viral hepatitis. The Global State of Harm Reduction has always been produced through a collaborative effort between community and civil society representatives and researchers.